![Bob van Gemen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bob van Gemen
Direttore/Membro del Consiglio presso Genome Diagnostics BV
Profilo
Bob van Gemen is a Non-Executive Director at Genome Diagnostics BV since 2021.
He was previously the Chief Executive Officer at PrimaGen Holding BV and ViroClinics Biosciences BV from 2011 to 2020.
He also worked as a Principal at Akzo Nobel NV.
Dr. van Gemen holds a doctorate degree from the University of Leiden.
Posizioni attive di Bob van Gemen
Società | Posizione | Inizio |
---|---|---|
Genome Diagnostics BV
![]() Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Direttore/Membro del Consiglio | 01/08/2021 |
Precedenti posizioni note di Bob van Gemen
Società | Posizione | Fine |
---|---|---|
ViroClinics Biosciences BV
![]() ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Amministratore Delegato | 01/08/2020 |
AKZO NOBEL N.V. | Corporate Officer/Principal | - |
PrimaGen Holding BV
![]() PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Amministratore Delegato | - |
Formazione di Bob van Gemen
University of Leiden | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
AKZO NOBEL N.V. | Process Industries |
Aziende private | 3 |
---|---|
PrimaGen Holding BV
![]() PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Commercial Services |
ViroClinics Biosciences BV
![]() ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Health Technology |
Genome Diagnostics BV
![]() Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Bob van Gemen